The Ras-association domain family (RASSF) members and their role in human tumourigenesis

Kolch, 2000, Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions, Biochem. J., 351, 289, 10.1042/0264-6021:3510289 Downward, 1998, Ras signalling and apoptosis, Curr. Opin. Genet. Dev., 8, 49, 10.1016/S0959-437X(98)80061-0 Ponting, 1996, A novel family of Ras-binding domains, Trends Biochem. Sci., 21, 422, 10.1016/S0968-0004(96)30038-8 Yamamoto, 1999, Ras-induced transformation and signaling pathway, J. Biochem. (Tokyo), 126, 799, 10.1093/oxfordjournals.jbchem.a022519 Sundaresan, 1992, p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus, Oncogene, 7, 1989 Hung, 1995, Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma, J. Am. Med. Assoc., 273, 558, 10.1001/jama.1995.03520310056030 Kok, 1997, Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes, Adv. Cancer Res., 71, 27, 10.1016/S0065-230X(08)60096-2 Sekido, 1998, Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene, Oncogene, 16, 3151, 10.1038/sj.onc.1201858 Sekido, 1998, Progress in understanding the molecular pathogenesis of human lung cancer, Biochim. Biophys. Acta, 1378, 21 Wistuba, 1999, Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma, Oncogene, 18, 643, 10.1038/sj.onc.1202349 Wistuba, 2000, High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints, Cancer Res., 60, 1949 Lerman, 2000, The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes, Cancer Res., 60, 6116 Dammann, 2000, Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3, Nat. Genet., 25, 315, 10.1038/77083 Wei, 1996, Construction of a 600-kilobase cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3: progress toward the isolation of a lung cancer TSG, Cancer Res., 56, 1487 Vavvas, 1998, Identification of Nore1 as a potential Ras effector, J. Biol. Chem., 273, 5439, 10.1074/jbc.273.10.5439 Burbee, 2001, Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression, J. Natl. Cancer Inst., 93, 691, 10.1093/jnci/93.9.691 Scheel, 2003, A novel interaction motif, SARAH, connects three classes of tumor suppressor, Curr. Biol., 13, R899, 10.1016/j.cub.2003.11.007 Kim, 1999, Substrate specificities and identification of putative substrates of ATM kinase family members, J. Biol. Chem., 274, 37538, 10.1074/jbc.274.53.37538 Newton, 1995, Protein kinase C. Seeing two domains, Curr. Biol., 5, 973, 10.1016/S0960-9822(95)00191-6 Hubbard, 2007, Ensembl 2007, Nucleic Acids Res., 35, D610, 10.1093/nar/gkl996 Khokhlatchev, 2002, Identification of a novel Ras-regulated proapoptotic pathway, Curr. Biol., 12, 253, 10.1016/S0960-9822(02)00683-8 Kamath, 2003, Systemic functional analysis of the Caenorhabditis elegans genome using RNAi, Nature, 421, 231, 10.1038/nature01278 Sönnichsen, 2005, Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans, Nature, 434, 462, 10.1038/nature03353 van der Weyden, 2005, The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis, Mol. Cell. Biol., 25, 8356, 10.1128/MCB.25.18.8356-8367.2005 Tommasi, 2005, Tumor susceptibility of Rassf1a knockout mice, Cancer Res., 65, 92, 10.1158/0008-5472.92.65.1 Polesello, 2006, The Drosophila RASSF homolog antagonizes the hippo pathway, Curr. Biol., 16, 2459, 10.1016/j.cub.2006.10.060 Jones, 2007, The epigenomics of cancer, Cell, 128, 683, 10.1016/j.cell.2007.01.029 Herman, 2003, Gene silencing in cancer in association with promoter hypermethylation, N. Engl. J. Med., 349, 2042, 10.1056/NEJMra023075 Dammann, 2005, The tumor suppressor RASSF1A in human carcinogenesis: an update, Histol. Histopathol., 20, 645 Hesson, 2007, The role of RASSF1A methylation in cancer, Dis. Markers, 23, 73, 10.1155/2007/291538 Antequera, 1990, High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines, Cell, 62, 503, 10.1016/0092-8674(90)90015-7 Jones, 1990, De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines, Proc. Natl. Acad. Sci. U. S. A., 87, 6117, 10.1073/pnas.87.16.6117 Chiu, 2007, Hypermethylation of RASSF1A in human and rhesus placentas, Am. J. Pathol., 170, 941, 10.2353/ajpath.2007.060641 Lehmann, 2002, Quantitative assessment of promoter hypermethylation during breast cancer development, Am. J. Pathol., 160, 605, 10.1016/S0002-9440(10)64880-8 Xing, 2004, Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis, Cancer Res., 64, 1664, 10.1158/0008-5472.CAN-03-3242 Yegnasubramanian, 2004, Hypermethylation of CpG islands in primary and metastatic human prostate cancer, Cancer Res., 64, 1975, 10.1158/0008-5472.CAN-03-3972 Wong, 2004, Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia, Clin. Cancer Res., 10, 994, 10.1158/1078-0432.CCR-0378-3 Pijnenborg, 2007, RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer, Ann. Oncol., 18, 491, 10.1093/annonc/mdl455 Astuti, 2001, RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours, Oncogene, 20, 7573, 10.1038/sj.onc.1204968 Dreijerink, 2001, The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis, Proc. Natl. Acad. Sci. U. S. A., 98, 7504, 10.1073/pnas.131216298 Lo, 2001, High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma, Cancer Res., 61, 3877 Dammann, 2003, Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis, Histol. Histopathol., 18, 665 Shivakumar, 2002, The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation, Mol. Cell. Biol., 22, 4309, 10.1128/MCB.22.12.4309-4318.2002 Kuzmin, 2002, The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells, Cancer Res., 62, 3498 Li, 2004, Inactivation of RASSF1C during in vivo tumor growth identifies it as a tumor suppressor gene, Oncogene, 23, 5941, 10.1038/sj.onc.1207789 Dallol, 2004, RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics, Cancer Res., 64, 4112, 10.1158/0008-5472.CAN-04-0267 Schagdarsurengin, 2005, A polymorphism at codon 133 of the tumor suppressor RASSF1A is associated with tumorous alteration of the breast, Int. J. Oncol., 27, 185 Lee, 2001, Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma, Cancer Res., 61, 6688 Harada, 2002, Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines, Oncogene, 21, 4345, 10.1038/sj.onc.1205446 Vos, 2000, Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis, J. Biol. Chem., 275, 35669, 10.1074/jbc.C000463200 Endoh, 2003, RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication, Int. J. Cancer, 106, 45, 10.1002/ijc.11184 Leon, 1977, Free DNA in the serum of cancer patients and the effect of therapy, Cancer Res., 37, 646 Stroun, 1989, Neoplastic characteristics of the DNA found in the plasma of cancer patients, Oncology, 46, 318, 10.1159/000226740 Herman, 1996, Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands, Proc. Natl. Acad. Sci. U. S. A., 93, 9821, 10.1073/pnas.93.18.9821 Ramirez, 2003, Serum DNA as a tool for cancer patient management, Rocz. Akad. Med. Bialymst., 48, 34 Wang, 2007, Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer, Lung Cancer, 56, 289, 10.1016/j.lungcan.2006.12.007 Topaloglu, 2004, Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer, Clin. Cancer Res., 10, 2284, 10.1158/1078-0432.CCR-1111-3 Zochbauer-Muller, 2003, Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers, Int. J. Cancer, 107, 612, 10.1002/ijc.11458 Schmiemann, 2005, Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study, Clin. Cancer Res., 11, 7728, 10.1158/1078-0432.CCR-05-0999 Belinsky, 2005, Gene promoter methylation in plasma and sputum increases with lung cancer risk, Clin. Cancer Res., 11, 6505, 10.1158/1078-0432.CCR-05-0625 Honorio, 2003, Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients, Oncogene, 22, 147, 10.1038/sj.onc.1206057 Dulaimi, 2004, Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients, Clin. Cancer Res., 10, 6189, 10.1158/1078-0432.CCR-04-0597 Lewis, 2005, Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk, Clin. Cancer Res., 11, 166, 10.1158/1078-0432.166.11.1 Rykova, 2004, Extracellular DNA in breast cancer—Cell-surface-bound, tumor-derived extracellular DNA in blood of patients with breast cancer and non-malignant tumors, Ann. N. Y. Acad. Sci., 1022, 217, 10.1196/annals.1318.033 Krassenstein, 2004, Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation, Clin. Cancer Res., 10, 28, 10.1158/1078-0432.CCR-0410-3 Battagli, 2003, Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients, Cancer Res., 63, 8695 Chan, 2003, Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients, Int. J. Cancer, 104, 611, 10.1002/ijc.10971 Dulaimi, 2004, Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel, Clin. Cancer Res., 10, 1887, 10.1158/1078-0432.CCR-03-0127 Friedrich, 2004, Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients, Clin. Cancer Res., 10, 7457, 10.1158/1078-0432.CCR-04-0930 Yates, 2006, Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls, Oncogene, 25, 1984, 10.1038/sj.onc.1209209 Roupret, 2007, Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage, Clin. Cancer Res., 13, 1720, 10.1158/1078-0432.CCR-06-2467 Ibanez de Caceres, 2004, Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients, Cancer Res., 64, 6476, 10.1158/0008-5472.CAN-04-1529 Fiegl, 2004, Methylated DNA collected by tampons—A new tool to detect endometrial cancer, Cancer Epidemiol. Biomark. Prev., 13, 882, 10.1158/1055-9965.882.13.5 Fiegl, 2005, Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients, Cancer Res., 65, 1141, 10.1158/0008-5472.CAN-04-2438 Murray, 2004, Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin’s lymphoma, Oncogene, 23, 1326, 10.1038/sj.onc.1207313 Chang, 2003, Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient, Int. J. Cancer, 105, 851, 10.1002/ijc.11162 Tomizawa, 2002, Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma, Clin. Cancer Res., 8, 2362 Wang, 2004, Value of p16(INK4a) and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer, Clin. Cancer Res., 10, 6119, 10.1158/1078-0432.CCR-04-0652 Toyooka, 2004, The relationship between aberrant methylation and survival in non-small-cell lung cancers, Br. J. Cancer, 91, 771, 10.1038/sj.bjc.6602013 Maruyama, 2004, Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma, Cancer, 100, 1472, 10.1002/cncr.20144 Choi, 2005, RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer, Int. J. Cancer, 115, 575, 10.1002/ijc.20916 Kim, 2003, Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer, Cancer Res., 63, 3743 Kang, 2004, Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia, J. Pathol., 202, 233, 10.1002/path.1503 Liu, 2002, Frequent hypermethylation of the RASSF1A gene in prostate cancer, Oncogene, 21, 6835, 10.1038/sj.onc.1205814 Maruyama, 2002, Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features, Clin. Cancer Res., 8, 514 Jeronimo, 2004, A quantitative promoter methylation profile of prostate cancer, Clin. Cancer Res., 10, 8472, 10.1158/1078-0432.CCR-04-0894 Muller, 2003, DNA methylation in serum of breast cancer patients: an independent prognostic marker, Cancer Res., 63, 7641 Mehrotra, 2004, Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung, Clin. Cancer Res., 10, 3104, 10.1158/1078-0432.CCR-03-0118 Maruyama, 2001, Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features, Cancer Res., 61, 8659 Catto, 2005, Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma, J. Clin. Oncol., 23, 2903, 10.1200/JCO.2005.03.163 Marsit, 2006, Carcinogen exposure and epigenetic silencing in bladder cancer, Ann. N. Y. Acad. Sci., 1076, 810, 10.1196/annals.1371.031 Dhawan, 2006, Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma, J. Pathol., 209, 336, 10.1002/path.1991 Jo, 2006, Association of promoter hypermethylation of the RASSF1A gene with prognostic parameters in endometrial cancer, Oncol. Res., 16, 205, 10.3727/000000006783981125 Liu, 2005, Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis, Mod. Pathol., 18, 1632, 10.1038/modpathol.3800490 Geli, 2007, The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma, Endocr. Relat. Cancer, 14, 125, 10.1677/ERC-06-0031 Hoon, 2004, Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients, Oncogene, 23, 4014, 10.1038/sj.onc.1207505 Hesson, 2004, Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas, Oncogene, 23, 2408, 10.1038/sj.onc.1207407 Byun, 2001, Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma, Cancer Res., 61, 7034 Li, 2005, Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma, Cancer, 104, 771, 10.1002/cncr.21215 Qian, 2005, Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas, Lab. Invest., 85, 464, 10.1038/labinvest.3700248 Katayama, 2007, Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion, Int. J. Cancer, 120, 2191, 10.1002/ijc.22576 Di Gioia, 2006, Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver, BMC Cancer, 6, 89, 10.1186/1471-2407-6-89 Calvisi, 2006, Ubiquitous activation of Ras and Jak/Stat pathways in human HCC, Gastroenterology, 30, 1117, 10.1053/j.gastro.2006.01.006 Woodson, 2004, Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: a histopathologic study of whole mount prostate specimens, Prostate, 60, 25, 10.1002/pros.20013 Woodson, 2004, A survey of gene-specific methylation in human prostate cancer among black and white men, Cancer Lett., 205, 181, 10.1016/j.canlet.2003.11.027 Aitchison, 2007, RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues, Prostate, 67, 638, 10.1002/pros.20475 Bastian, 2005, Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci, Clin. Cancer Res., 11, 4097, 10.1158/1078-0432.CCR-04-1832 van Engeland, 2002, K-ras mutations and RASSF1A promoter methylation in colorectal cancer, Oncogene, 21, 3792, 10.1038/sj.onc.1205466 Dammann, 2003, Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma, Oncogene, 22, 3806, 10.1038/sj.onc.1206582 Li, 2003, RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer, Neoplasia, 5, 362, 10.1016/S1476-5586(03)80029-5 Kim, 2003, Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer, Cancer Res., 63, 6206 Irimia, 2004, CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer, Oncogene, 23, 8695, 10.1038/sj.onc.1207914 Reifenberger, 2004, Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas, Int. J. Cancer, 109, 377, 10.1002/ijc.11722 Chen, 2006, Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer, Oncol. Rep., 15, 1281 Schagdarsurengin, 2002, Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma, Cancer Res., 62, 3698 Lazcoz, 2006, Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma, BMC Cancer, 6, 254, 10.1186/1471-2407-6-254 Zhang, 2007, CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma, Clin. Cancer Res., 13, 944, 10.1158/1078-0432.CCR-06-2268 Kuzmin, 2003, GP, Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection, Cancer Res., 63, 1888 Dong, 2003, Epigenetic inactivation of RASSF1A in head and neck cancer, Clin. Cancer Res., 9, 3635 Cohen, 2003, The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix, Clin. Cancer Res., 9, 2981 Yu, 2003, Hypermethylation of the tumor suppressor gene Rassf1a and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers, Int. J. Cancer, 105, 204, 10.1002/ijc.11051 Kang, 2002, Epstein–Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma, Am. J. Pathol., 160, 787, 10.1016/S0002-9440(10)64901-2 Toyooka, 2001, DNA methylation profiles of lung tumors, Mol. Cancer Ther., 1, 61 Toyooka, 2002, Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells, Oncogene, 21, 4340, 10.1038/sj.onc.1205381 Zhang, 2002, High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma, Mol. Carcinog., 35, 85, 10.1002/mc.10076 Chow, 2004, RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma, Int. J. Cancer, 109, 839, 10.1002/ijc.20079 Ji, 2002, Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo, Cancer Res., 62, 2715 Amaar, 2005, Ras-association domain family 1 protein, RASSF1C, is an IGFBP-5 binding partner and a potential regulator of osteoblast cell proliferation, J. Bone Miner. Res., 20, 1430, 10.1359/JBMR.050311 Amaar, 2006, Ras association domain family 1C protein stimulates human lung cancer cell proliferation, Am. J. Physiol., Lung Cell. Mol. Physiol., 291, L1185, 10.1152/ajplung.00072.2006 Estrabaud, 2007, RASSF1C, an isoform of the tumor suppressor RASSF1A, promotes the accumulation of beta-catenin by interacting with betaTrCP, Cancer Res., 67, 1054, 10.1158/0008-5472.CAN-06-2530 Smith, 2002, Cre-loxP chromosome engineering of a targeted deletion in the mouse corresponding to the 3p21.3 region of homozygous loss in human tumours, Oncogene, 21, 4521, 10.1038/sj.onc.1205530 Liu, 2003, Control of microtubule stability by the RASSF1A tumor suppressor, Oncogene, 22, 8125, 10.1038/sj.onc.1206984 Song, 2004, The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC–Cdc20 complex, Nat. Cell Biol., 6, 129, 10.1038/ncb1091 Vos, 2004, A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability, Cancer Res., 64, 4244, 10.1158/0008-5472.CAN-04-0339 Rong, 2004, Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G2/M arrest, Oncogene, 23, 8216, 10.1038/sj.onc.1207901 Liu, 2002, Novel complex integrating mitochondria and the microtubular cytoskeleton with chromosome remodeling and tumor suppressor RASSF1 deduced by in silico homology analysis, interaction cloning in yeast, and colocalization in cultured cells, In Vitro Cell Dev. Biol. Anim., 38, 582, 10.1290/1543-706X(2002)38<582:NCIMAT>2.0.CO;2 Dallol, 2007, Depletion of the Ras association domain family 1, isoform A-associated novel microtubule-associated protein, C19ORF5/MAP1S, causes mitotic abnormalities, Cancer Res., 67, 492, 10.1158/0008-5472.CAN-06-3604 Liu, 2005, Specificity of the methylation-suppressed A isoform of candidate tumor suppressor RASSF1 for microtubule hyperstabilization is determined by cell death inducer C19ORF5, Cancer Res., 65, 1830, 10.1158/0008-5472.CAN-04-3896 Agathanggelou, 2003, Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma, Cancer Res., 63, 5344 Baksh, 2005, The tumor suppressor RASSF1A and MAP-1 link death receptor signalling to bax conformational change and cell death, Mol. Cell, 18, 637, 10.1016/j.molcel.2005.05.010 Fenton, 2004, Identification of the E1A-regulated transcription factor p120E4F as an interacting partner of the RASSF1A candidate tumor suppressor gene, Cancer Res., 64, 102, 10.1158/0008-5472.CAN-03-2622 Ahmed-Choudhury, 2005, Transcriptional regulation of cyclin A2 by RASSF1A through the enhanced binding of p120E4F to the cyclin A2 promoter, Cancer Res., 65, 2690, 10.1158/0008-5472.CAN-04-3593 Whang, 2005, RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression, Cancer Res., 65, 3682, 10.1158/0008-5472.CAN-04-2792 Song, 2004, Control of APC–Cdc20 by the tumor suppressor RASSF1A, Cell Cycle, 3, 574, 10.4161/cc.3.5.887 Song, 2005, The centrosomal protein RAS association domain family protein 1A (RASSF1A)-binding protein 1 regulates mitotic progression by recruiting RASSF1A to spindle poles, J. Biol. Chem., 280, 3920, 10.1074/jbc.M409115200 Mathe, 2004, RASSF1A, the new guardian of mitosis, Nat. Genet., 36, 117, 10.1038/ng0204-117 Jackson, 2004, Linking tumor suppression, DNA damage and the anaphase-promoting complex, Trends Cell Biol., 14, 331, 10.1016/j.tcb.2004.05.005 Guo, 2007, RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network, Curr. Biol., 17, 700, 10.1016/j.cub.2007.02.055 Bhalla, 2003, Microtubule-targeted anticancer agents and apoptosis, Oncogene, 22, 9075, 10.1038/sj.onc.1207233 Walczak, 2000, Microtubule dynamics and tubulin interacting proteins, Curr. Opin. Cell Biol., 12, 52, 10.1016/S0955-0674(99)00056-3 R. Rong, L.Y. Jiang, M.S. Sheikh, Y. Huang, Mitotic kinase Aurora—A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation. Oncogene Jun 11 (2007) [Epub ahead of print, doi:10.1038/sj.onc.1210575]. Armesilla, 2004, Novel functional interaction between the plasma membrane Ca2+ pump 4b and the proapoptotic tumor suppressor Ras-associated factor 1 (RASSF1), J. Biol. Chem., 23, 31318, 10.1074/jbc.M307557200 Wassmann, 2001, Mitotic checkpoints: from yeast to cancer, Curr. Opin. Genet. Dev., 11, 83, 10.1016/S0959-437X(00)00161-1 Denko, 1994, The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle, Proc. Natl. Acad. Sci. U. S. A., 91, 5124, 10.1073/pnas.91.11.5124 Saavedra, 2000, The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway, Oncogene, 19, 3948, 10.1038/sj.onc.1203723 Ortiz-Vega, 2002, The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1, Oncogene, 21, 1381, 10.1038/sj.onc.1205192 Rabizadeh, 2004, The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death, J. Biol. Chem., 279, 29247, 10.1074/jbc.M401699200 Praskova, 2004, Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras, Biochem. J., 381, 453, 10.1042/BJ20040025 Avruch, 2005, Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases, Methods Enzymol., 407, 290, 10.1016/S0076-6879(05)07025-4 Vos, 2006, The RASSF1A tumor suppressor activates Bax via MOAP-1, J. Biol. Chem., 281, 4557, 10.1074/jbc.M512128200 Kitagawa, 2006, Release of RASSF1C from the nucleus by Daxx degradation links DNA damage and SAPK/JNK activation, EMBO J., 25, 3286, 10.1038/sj.emboj.7601212 Dallol, 2005, Involvement of the RASSF1A tumor suppressor gene in controlling cell migration, Cancer Res., 65, 7653, 10.1158/0008-5472.CAN-05-0247 Comincini, 2001, Isolation and molecular characterization of rasfadin, a novel gene in the vicinity of the bovine prion gene, Mamm. Genome, 12, 150, 10.1007/s003350010239 Hesson, 2005, CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations, Oncogene, 24, 3987, 10.1038/sj.onc.1208566 Loveland, 2005, VEGA, the genome browser with a difference, Brief Bioinfom., 6, 189, 10.1093/bib/6.2.189 Vos, 2003, RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor, J. Biol. Chem., 278, 28045, 10.1074/jbc.M300554200 Akino, 2005, The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer, Gastroenterology, 129, 156, 10.1053/j.gastro.2005.03.051 Nosho, 2007, Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers, Carcinogenesis, 28, 1364, 10.1093/carcin/bgl246 Park, 2007, Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers, Int. J. Cancer, 120, 7, 10.1002/ijc.22276 Kaira, 2007, Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers, Int. J. Oncol., 31, 169 Endoh, 2005, RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer, Br. J. Cancer, 93, 1395, 10.1038/sj.bjc.6602854 Zhang, 2007, Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma, Int. J. Cancer, 120, 32, 10.1002/ijc.22185 Sakamoto-Hojo, 2003, Gene expression profiles in human cells submitted to genotoxic stress, Mutat. Res., 544, 403, 10.1016/j.mrrev.2003.07.004 Eckert, 2004, Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis, Cancer Res., 64, 4585, 10.1158/0008-5472.CAN-04-0396 Tommasi, 2002, RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1, Oncogene, 21, 2713, 10.1038/sj.onc.1205365 Eckfeld, 2004, RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family, Cancer Res., 64, 8688, 10.1158/0008-5472.CAN-04-2065 Chow, 2004, Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma, Oncol. Rep., 12, 781 Agathanggelou, 2001, Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours, Oncogene, 22, 1509, 10.1038/sj.onc.1204175 Reuther, 2000, Analysis of function and regulation of proteins that mediate signal transduction by use of lipid-modified plasma membrane-targeting sequences, Methods Enzymol., 327, 331, 10.1016/S0076-6879(00)27288-1 Hesson, 2003, NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers, Oncogene, 22, 947, 10.1038/sj.onc.1206191 Vos, 2003, The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung, J. Biol. Chem., 278, 21938, 10.1074/jbc.M211019200 Aoyama, 2004, Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases, Oncogene, 23, 3426, 10.1038/sj.onc.1207486 Nakamura, 2005, RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors, Lab. Invest., 85, 1065, 10.1038/labinvest.3700306 Foukakis, 2006, The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARγ fusion, J. Clin. Endocrinol. Metab., 91, 1143, 10.1210/jc.2005-1372 Steiner, 1996, High-density mapping of chromosomal arm 1q in renal collecting duct carcinoma: region of minimal deletion at 1q32.1–32.2, Cancer Res., 56, 5044 Chen, 2003, The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas, Cancer Cell, 4, 405, 10.1016/S1535-6108(03)00269-1 Morris, 2003, Multigene methylation analysis of Wilms’ tumour and adult renal cell carcinoma, Oncogene, 22, 6794, 10.1038/sj.onc.1206914 Macheiner, 2006, NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma, J. Hepatol., 45, 81, 10.1016/j.jhep.2005.12.017 Moshnikova, 2006, The growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathway, J. Biol. Chem., 281, 8143, 10.1074/jbc.M511837200 Hwang, 2007, Structural insight into dimeric interaction of the SARAH domains from Mst1 and RASSF family proteins in the apoptosis pathway, Proc. Natl. Acad. Sci. U. S. A., 104, 9236, 10.1073/pnas.0610716104 Kinashi, 2005, Regulation of immune cell adhesion and migration by regulator of adhesion and cell polarization enriched in lymphoid tissues, Immunology, 116, 164, 10.1111/j.1365-2567.2005.02214.x Katagiri, 2003, RAPL, a Rap1-binding molecule that mediates Rap1-induced adhesion through spatial regulation of LFA-1, Nat. Immunol., 4, 741, 10.1038/ni950 Katagiri, 2004, Crucial functions of the Rap1 effector molecule RAPL in lymphocyte and dendritic cell trafficking, Nat. Immunol., 5, 1045, 10.1038/ni1111 Fujita, 2005, Local activation of Rap1 contributes to directional vascular endothelial cell migration accompanied by extension of microtubules on which RAPL, a Rap1-associating molecule, localizes, J Biol. Chem., 280, 5022, 10.1074/jbc.M409701200 Katagiri, 2006, Spatiotemporal regulation of the kinase Mst1 by binding protein RAPL is critical for lymphocyte polarity and adhesion, Nat. Immunol., 7, 919, 10.1038/ni1374 Ishiguro, 2006, Nore1B regulates TCR signaling via Ras and Carma1, Cell. Signal., 18, 1647, 10.1016/j.cellsig.2006.01.015 Ikeda, 2007, Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways, Exp. Cell Res., 313, 1484, 10.1016/j.yexcr.2007.02.013 N.P. Allen, H. Donninger, M.D. Vos, K. Eckfeld, L. Hesson, L. Gordon, M.J. Birrer, F. Latif, G.J. Clark, RASSF6 is a novel member of the RASSF family of tumor suppressors, Oncogene (2007) Advance online publication 2 April 2007 (doi:10.1038/sj.onc.1210440). Diep, 2004, Genome characteristics of primary carcinomas, local recurrences, carcinomatoses, and liver metastases from colorectal cancer patients, Mol. Cancer, 3, 6, 10.1186/1476-4598-3-6 Takai, 2003, The CpG island searcher: a new WWW resource, In Silico Biol., 3, 235 Hull, 2004, Haplotype mapping of the bronchiolitis susceptibility locus near IL8, Hum. Genet., 114, 272, 10.1007/s00439-003-1038-x Bitko, 2004, Activation of cytokines and NF-kappa B in corneal epithelial cells infected by respiratory syncytial virus: potential relevance in ocular inflammation and respiratory infection, BMC Microbiol., 4, 28, 10.1186/1471-2180-4-28 Weitzel, 1992, The HRAS1 gene cluster: two upstream regions recognizing transcripts and a third encoding a gene with a leucine zipper domain, Genomics, 14, 309, 10.1016/S0888-7543(05)80221-6 Kiel, 2005, Recognizing and defining true Ras binding domains II: in silico prediction based on homology modelling and energy calculations, J. Mol. Biol., 348, 759, 10.1016/j.jmb.2005.02.046 Wohlgemuth, 2005, Recognizing and defining true Ras binding domains I: biochemical analysis, J. Mol. Biol., 348, 741, 10.1016/j.jmb.2005.02.048 Falvella, 2006, Identification of RASSF8 as a candidate lung tumor suppressor gene, Oncogene, 25, 3934, 10.1038/sj.onc.1209422 Falvella, 2007, Common polymorphisms in D12S1034 flanking genes RASSF8 and BHLHB3 are not associated with lung adenocarcinoma risk, Lung Cancer, 56, 1, 10.1016/j.lungcan.2006.11.008 Debeer, 2002, The fibulin-1 gene (FBLN1) is disrupted in a t(12;22) associated with a complex type of synpolydactyly, J. Med. Genet., 39, 98, 10.1136/jmg.39.2.98 Hulo, 2006, The PROSITE database, Nucleic Acids Res., 34, D227, 10.1093/nar/gkj063 Liu, 2007, The tumor suppressor RASSF1A does not interact with Cdc20, an activator of the anaphase-promoting complex, Cell Cycle, 6, 1663, 10.4161/cc.6.13.4435